Massachusetts Institute of Technology

Dana-farber-cancer Institute Inc.

Boston University

Unversität Zürich

Angela N Koehler

Shelby Doyle

Eric Stefan

Francisco Caballero

Nicholas B Struntz

Andrew Raymond Chen

Helen L Evans

Becky Leifer

Dylan Vijith Neel

Paula T Hammond

Arturo Jose Vegas

David C Freeman

Marco Wachtel

Natalie Boehnke

Daniel Sheehy

Andre Richters

Kelly Tan

Stephen Thomas Nestor

Luke Ceo

Madeleine Henley

Sean Quinnell

Beat W Schaefer

Joelle Payne Straehla

SLC46A3 has been identified as a lipid-based nanoparticle-specific biomarker predictive of nanoparticle-cancer cell affinity. SLC46A3 has a strong inverse association with lipid-based nanoparticle uptake across multiple nanoparticle formulations. Tissues with decreased expression levels of SLC46A3 have a greater uptake of lipid-based nanoparticles. The inverse relationship of SLC46A3 expression in tumor tissue and affinity for lipid-based nanoparticles has therapeutic and diagnostic implications, including cancer therapy and diagnosis, and identification of patients most likely to benefit from a lipid-based nanotherapeutic for improved stratification in clinical trials.

Solute carrier family 46 member 3 (SLC46A3) as marker for lipid-based nanoparticle cancer therapy and diagnostics

The technology described herein is directed to IL-4 and/or IL-13 inhibitors and uses thereof.

Small molecule inhibitors of Interleukin-4

The present disclosure provides compounds having the general formula P-L-U, or pharmaceutically acceptable salts thereof, wherein P is a FOXO1 fusion protein binding moiety, L is a bivalent linker, and U is an ubiquitin ligase binding moiety. Also provided are pharmaceutical compositions containing such compounds and methods of using such compounds.

Small molecule binders of the oncogenic fusion transcription factor PAX3-FOXO1

Provided herein are compounds useful for modulating the activity of an androgen receptor, or a variant thereof, and related compositions and methods. Compounds of the invention are useful for antagonizing the androgen receptor splice variant AR-v7, and for the treatment of castration-resistant prostate cancer.

Small molecule modulators of the androgen receptor

The present disclosure provides compounds of Formula (I'), Formula (I), Formula (II), Formula (II-A), Formula (III), and Formula (IV). The compounds described herein are MAX binders and/or modulators of Myc, Mad, or Mxi1 (e.g., inhibitors of Myc, Mad, or Mxi1), and may be useful in treating a subject with a disease associated with Myc, such as proliferative diseases (e.g., cancer). Also provided in the present disclosure are pharmaceutical compositions and kits including the compounds described herein, as well as methods of using and uses of the compounds, compositions, and kits. 

Max binders as MYC modulators and uses thereof

The present disclosure provides compounds of Formula (I-a), Formula (I), and Formula (II). The compounds described herein may be Myc modulators (e.g., Myc inhibitors) and may be useful in treating in a subject in need thereof diseases associated with Myc and proliferative diseases (e.g., cancer). Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including a compound described herein. 

Myc modulators and uses thereof

Growing community of inventors

Belmont, MA, United States of America

Angela N Koehler